Thursday, October 15, 2026

Lumber Futures Bearish By 19% In The Last 21 Sessions

Lumber Futures Bearish By 19% In The Last 21 Sessions

(VIANEWS) - Lumber (LBS) has been up by 19.8% for the last 21 sessions. At 20:56 EST on Tuesday, 14 March, Lumber (LBS) is $336.50.

Volume

Today's last reported volume for Lumber is 312, 99.99% below its average volume of 18903374.11.

Volatility

Lumber's last week, last month's, and last quarter's current intraday variation average was 4.82%, 3.43%, and 4.38%, respectively.

Lumber's highest amplitude of average volatility was 6.08% (last week), 4.31% (last month), and 4.38% (last quarter), respectively.

Commodity Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Lumber's commodity is considered to be oversold (<=20).

News about

  • According to FXStreet on Monday, 13 March, "Although a five-week-old support line restricts immediate WTI crude oil downside near $75.00, a daily closing beyond the 50-DMA hurdle surrounding $77.75 becomes necessary for the Crude Oil price to keep the buyers in the driver's seat."
  • Crude oil forecast: crude oil continues to trade in a range - 13 March 2023. According to DailyForex on Monday, 13 March, "The WTI Crude Oil and Brent markets are experiencing uncertainty around demand, leading to a range-bound market for short-term moves. ", "Like the WTI Crude Oil market, Brent is also facing the same problems of uncertainty around demand. "
  • Crude oil forecast: crude oil tests the bottom of its range - 14 March 2023. According to DailyForex on Tuesday, 14 March, "The West Texas Intermediate (WTI) Crude Oil market has been struggling as of late, with concerns mounting about the demand for oil in the current economic climate. "

More news about Lumber (LBS).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com